Are progestins really necessary as part of a combined HRT regimen?

  title={Are progestins really necessary as part of a combined HRT regimen?},
  author={D. Sturdee},
  pages={79 - 84}
Abstract For many years it has been perceived wisdom that hormone replacement therapy for women with a uterus should include a progestin to prevent the proliferative effects of estrogen on the endometrium and endometrial cancer. But, with the reports from the Women's Health Initiative (WHI) and Million Women Study indicating that such regimens are associated with an increased risk of breast cancer, whereas unopposed estrogen may not increase this risk, or even reduce it, it is pertinent to… Expand
Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference
Micronized progesterone and dydrogesterone appear to be the safest options, with lower associated cardiovascular, thromboembolic, and breast cancer risks compared with other progestogens, and are the first-choice options for use in ‘special situations,’ such as in women with high-density breast tissue, diabetes, obesity, smoking, and risk factors for venous throm boembolism. Expand
Pharmacotherapies for Menopause Management: Hormonal Options
It is known that benefits may exceed risks for the majority of symptomatic postmenopausal women who at the time of initiation of MHT are less than age 60 or less than 10 years since the onset of menopause and at low baseline risk for cardiovascular events and there appears to be differences in the risk/benefit profiles between different types of hormonal regimens. Expand
The use of high-dose estrogens for the treatment of breast cancer.
Taking into account their side-effect profile together with their observed clinical efficacy, high-dose estrogens should be considered a valuable alternative to chemotherapy in selected patients. Expand
Hormones and risk of breast and gynecological cancer
Oral contraception increases breast cancer risk but is protective against ovarian and endometrial cancers and the influence of ovarian hyperstimulation has been controversially discussed and no clear association with these hormone-dependent tumors has been observed. Expand
Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer
The role of hormone therapy in women with endometrial cancer and risk of endometrium cancer in women on hormones will be discussed in this chapter. Expand
Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites
Greater consideration should be given to how the immunomodulatory effects these compounds alter the outcome of diseases at mucosal sites beyond the reproductive tract, which has profound implications for women’s health. Expand
The breast cancer epidemic: 10 facts
The epidemiological evidence of preventable causes of breast cancer is reviewed to highlight the need to understand more fully the rationale behind the increasing frequency and severity of the disease. Expand


Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
Differences in chemical structure, metabolism, pharmacokinetics, affinity, potency, and efficacy via steroid receptors, intracellular action, and biological and clinical effects confirm the absence of a class effect of progestogens. Expand
Risk of endometrial cancer following estrogen replacement with and without progestins.
The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestin use, and Continuously added progESTins may be needed to minimize the endometricrial cancer risk associated with estrogen replacement therapy. Expand
Micronized progesterone and its impact on the endometrium and breast vs. progestogens
  • A. Gompel
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2012
Micronized progesterone does not increase cell proliferation in breast tissue in postmenopausal women compared with synthetic medroxyprogesterone acetate (MPA), and experimental evidence suggests that the opposing effects of MPA and micronization on breast tissue are related to the non-specific effects ofMPA. Expand
The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?
Patients with an initial thin distinct endometrial echo can begin with unopposed estrogen, and the advantage for the successful patient is less progestogen exposure, as little as 24 days per year in most patients, and less bleeding. Expand
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo, and provides additional support for caution in the use of continuous combined hormones. Expand
Intrauterine application of progestins in hormone replacement therapy: a review
  • F. Riphagen
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2000
Intrauterine use of progestins, especially levonorgestrel, by purpose-designed systems as part of combined HRT, is a new way of administration and carries good benefits, while some aspects require more clinical evidence. Expand
Regulation of estrogen/progestogen receptors in the endometrium.
  • R. Casper
  • Medicine
  • International journal of fertility and menopausal studies
  • 1996
A novel interrupted progestin HRT regimen is developed in which estrogen is given continuously, but with progestsin administered in a 3- days-on and 3-days-off schedule to prevent total receptor down-regulation by allowing estrogen to up-regulate estrogen and progest in receptors during the progestIn-free periods. Expand
The impact of different HRT regimens on compliance.
Epidemiological data strongly suggest a substantial improvement of quality of life for post-menopausal women using hormonal replacement therapy (HRT), Nevertheless, reluctance of women to choose HRT is high and general recommendations are difficult to justify. Expand
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence and prognosis after diagnosis on combined hormone therapy is similar to that of nonusers, and increased breastcancer mortality can be expected. Expand
Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group.
It is concluded that the long cycle HRT modality investigated did not improve compliance and may increase the risk of endometrial hyperplasia and eventually cancer compared to conventional HRT with a monthly cycle. Expand